Mike Casia serves as our Interim Head of U.S. Commercial & Government Affairs of Organon and President of Organon Canada Inc. He is responsible for ensuring Organon achieves its strategic and commercial objectives in those geographies. Mike has led Organon Canada since spin in 2021. Under his leadership, the Canadian team achieved double-digit revenue growth […]
https://www.organon.com/leadership/mike-casia-interim-head-of-u-s-commercial-government-affairs/
Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary. HADLIMA is an FDA-approved biosimilar to HUMIRA for the treatment of specific autoimmune or autoinflammatory conditions such as rheumatoid arthritis, Crohn’s disease, hidradenitis suppurativa, and plaque psoriasis (see full indications below). "America’s veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together,” said Kevin Ali, Organon CEO. “We applaud the VA for its leadership in championing biosimilars and including all three of Organon’s biosimilars available in the US on its formulary." HADLIMA was launched in the US to offer patients a
https://www.organon.com/news/organon-announces-hadlima-adalimumab-bwwd-has-been-exclusively-selected-by-the-us-department-of-veterans-affairs-va-replacing-humira-on-its-national-formulary/
Juan Camilo leads the advancement of a diverse portfolio of medicines and solutions that focus on improving the health of women and all patients. In this role, he contributes his strategic and dynamic perspective, overseeing and strengthening the organization’s scientific, medical and regulatory capabilities in support of its long-term mission. Juan Camilo has over 20 years […]
https://www.organon.com/leadership/juan-camilo-arjona-ferreira-head-of-research-development-chief-medical-officer/
JADA Rapidly and Effectively Controlled Bleeding Due to PPH, 1 Reinforcing Pivotal Study Results 1 PPH is a Significant Cause of Maternal Morbidities in the U.S. 2,3,4,5 New Exploratory Post-Hoc Analysis Examined the Relationship Between Reported Severe Maternal Morbidity (SMM) Outcomes and Cumulative Blood Loss Prior to JADA Insertion 1 Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gy necology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA ® System. 1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management
https://www.organon.com/news/first-real-world-observational-study-of-the-jadasystem-a-medical-device-to-control-postpartum-hemorrhage-pph-published-in-acogs-obstetrics-gynecology/
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company’s global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs. Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development. Dr. Arjona Ferreira brings over two decades of clinical research and development experience and a strong background in women’s health. Most recently, he was CMO of Myovant Sciences Inc., and has previously held leadership roles in women’s health and other therapeutic areas at Shionogi and Merck, known as MSD outside of the United States and Canada. Earlier in his career, Dr. Arjona Ferreira practiced as an OB-GYN in university hospitals and private practice.
https://www.organon.com/news/organon-bolsters-research-development-expertise-with-two-leadership-appointments/
Sub-analysis of children with atopic dermatitis aged 2-17 in pivotal Phase 3 trials revealed early and clinically meaningful improvements in vIGA-AD ™ and EASI-75 (skin clearance and severity), POEM (patient-reported outcomes) and PP-NRS (itch), regardless of comorbidity status, at week 8 Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida, on November 8, 2025. The new data demonstrate that VTAMA cream provided early and consistent response for children aged 2-17 with atopic dermatitis (AD), with or without atopic comorbidities such as asthma, allergic rhinitis and food allergies. “As many children with atopic dermatitis may also be living with potential comorbidities such as
https://www.organon.com/news/new-data-show-early-and-consistent-response-to-vtama-tapinarof-cream-1-in-children-aged-2-with-atopic-dermatitis-including-those-with-associated-comorbidities/
Ramona Sequeira Ramona Sequeira has over 30 years of experience in the biopharmaceutical industry across multiple geographies and healthcare systems globally. Ms. Sequeira spent 10 years at Takeda Pharmaceutical Company, serving first as President, Takeda Pharmaceuticals USA. During this time, she oversaw a three-fold expansion of Takeda’s US business through organic and in-organic growth, contributing over […]
https://www.organon.com/leadership/ramona-sequeira/
To Women, Girls, and Frankly Everyone: A growing health concern is impacting women: contraception and reproductive misinformation around access and care.1,2 It comes amidst a particularly fragile time for reproductive health for women and girls in the US,3 especially for the more than 19 million women living in a contraceptive desert, according to Power to […]
https://www.organon.com/stories/dr-charlotte-owens-addresses-contraception-and-reproductive-health-misinformation/
Meet Enrica Enrica is a wife and mother of two, living in Italy, where she balances family life and her love of travel with her role as a member of the Medical Affairs team at Organon. Living with severe migraine has led her to make several career shifts over the years – her dream of […]
https://www.organon.com/stories/enricas-journey-with-migraine/
Welcome to “Minds Behind the Science,” a series dedicated to celebrating the achievements of physicians, researchers, and healthcare professionals. At Organon, we believe in the power of diverse voices and perspectives to help drive innovation and improve health outcomes. Through this series, we will highlight the inspiring stories that are driving the people of Organon […]
https://www.organon.com/stories/minds-behind-the-science/
